Daily Briefing – July 4 Weekend Update: U.S. Markets Closed for Independence Day, Europe Closes at Record Highs, OPEC+ Meets Sunday, and Fed Minutes, SpaceX Index Flow and a VERA FDA Decision Headline the Week Ahead

Saturday, July 4, 2026 is a full market holiday: U.S. equities are closed for Independence Day and do not reopen until Monday, July 6, so today is about framing the holiday-shortened week and the busy calendar just ahead. The last full session on July 2 left the Dow at a record above 52,900 while the Nasdaq stayed pressured by semiconductors, and Friday’s European session pushed on to fresh highs as the soft U.S. June jobs report eased rate-hike pressure. The week of July 6–10 is light on data but heavy on scheduled catalysts: an OPEC+ output meeting brought forward to Sunday, June FOMC minutes on Wednesday, the first Q2 earnings from PepsiCo and Delta, SpaceX’s record-fast Nasdaq-100 inclusion before the July 7 open, and a Vera Therapeutics FDA decision due July 7. With volumes thin and the tape closed, weekend headlines on oil, rates and geopolitics carry more weight than usual into Monday’s reopen.

Weekend recap and global tape
  • SPY / QQQ / DIA— U.S. markets are closed Saturday for Independence Day and reopen Monday, July 6. The reference point is still the July 2 close, when the Dow finished at a record above 52,900 and the S&P 500 was roughly flat while the Nasdaq lagged on continued semiconductor weakness.Holiday
  • Europe— European equities kept climbing in Friday’s session while Wall Street was shut: the pan-European Stoxx 600 rose about 0.7% to a fresh 52-week high, Germany’s DAX added roughly 0.85% and France’s CAC 40 gained about 0.5%, with defensive utilities leading. Softer U.S. jobs data continued to support the rate-relief tone across the region.Global
  • Payrolls— June nonfarm payrolls rose just 57,000, well short of expectations near 110,000, with unemployment at 4.2% flattered by a drop in participation to 61.5% and prior months revised lower by a combined 74,000. The report is the backdrop for every rate and rotation debate into the new week.Macro
  • Semis— Semiconductors remain the market’s weak link after the SOX index dropped sharply during the holiday-shortened week, giving back part of a quarter in which it had roughly doubled. Whether chips stabilize or extend the AI-valuation reset is the single most important leadership question for Monday.Leadership
  • TSLA— Tesla’s Q2 delivery beat at 480,126 vehicles is now digested rather than pending; the stock faded the news last week. Monday’s test is whether buyers defend the reaction or the EV group treats the beat as already priced ahead of the quarterly report.EV
Rates, oil and cross-asset
  • Fed path— After the soft payrolls print, fed-funds futures cut the odds of a September hike to roughly 51% from about 63%, and trimmed the chance of a move by year-end to about 76% from 83%. A July hike is now seen as unlikely, but the tightening debate is postponed, not settled.Rates
  • Treasuries— The reaction in rates was not a clean rally: the two-year yield held near 4.13% while the long end firmed, with the 10-year around 4.48% and the 30-year near 4.99%. Lower hike odds at the front end alongside a firmer long end keeps the curve, not just the Fed, in focus for Monday.Yields
  • Oil / WTI— WTI crude drifted to just above $68 a barrel, down close to 20% over two weeks as the geopolitical premium faded. That decline sets up a market already positioned for softer prices heading into the weekend OPEC+ decision.Energy
  • DXY / GLD— The softer jobs data leaned on the dollar and supported gold, but the firmer long end complicates the simple rate-relief trade. The cleanest confirmation Monday is a contained dollar and stable credit rather than a dollar move driven by growth fear.Cross-Asset
U.S.-listed / U.S.-quoted focus

July 2026 Biotech Catalysts

A clean homepage grid focused on tradable U.S. tickers with verified FDA/PDUFA calendar days. Each card links back to Merlintrader coverage, stock hubs or internal ticker pages.

8Tickers
8FDA / PDUFA
Jul 1Updated
FDA / PDUFA Merlintrader key watch U.S. ADR / OTC ADR Private and non-U.S. records excluded
Jul07
PDUFA
$VERA Vera Therapeutics — atacicept Priority Review for adults with IgA nephropathy. One of July’s cleanest renal biotech catalysts. Open Merlintrader hub →
Jul07
PDUFA
$AZN AstraZeneca — Enhertu Priority Review in post-neoadjuvant HER2+ early breast cancer. Large-cap oncology / ADC read-through.
Jul17
PDUFA
$CELC Celcuity — gedatolisib HR+/HER2- PIK3CA wild-type advanced breast cancer. Priority Review oncology catalyst. Open Merlintrader hub →
Jul23
FDA Date
$SNY Sanofi — Sarclisa SC Revised FDA target action date for subcutaneous isatuximab. Multiple myeloma convenience / lifecycle catalyst.
Jul24
PDUFA
$OTSKY Otsuka — centanafadine Priority Review for ADHD in children, adolescents and adults. U.S. OTC/Pink ADR; CNS / ADHD market read-through.
Jul26
PDUFA
$MNKD MannKind — FUROSCIX ReadyFlow ReadyFlow Autoinjector sNDA. Commercial execution catalyst for CHF/CKD edema. Open Merlintrader hub →
Jul29
PDUFA
$OTLK Outlook — ONS-5010 / Lytenava Class 1 review for wet AMD BLA resubmission. Highly sensitive ophthalmology small-cap setup. Open Merlintrader hub →
Jul30
PDUFA
$VTRS Viatris — low-dose estrogen weekly patch 505(b)(2) contraceptive weekly patch. Pipeline milestone, less binary than small-cap biotech.

Merlintrader key watchlist

$VERA — Jul 7 $CELC — Jul 17 $MNKD — Jul 26 $OTLK — Jul 29 $VTRS — Jul 30

Clean-data note

Excluded: private companies, non-U.S.-quoted records, congress-only items, month-only trial estimates, AI-detected records without a confirmed day, already decided events such as $CORT and $LLY imlunestrant (FDA-approved 2025), and non-July records such as $VRDN.

Educational content only — not investment advice. Full catalyst calendar FDA SEC EDGAR

Biotech Catalyst Lookup

Type a ticker to get an AI-generated snapshot of the next catalyst (PDUFA, clinical data, regulatory events) with a link to the primary source.

Disclaimer. This content is for educational and informational purposes only. It is not investment advice and not a recommendation to buy or sell any security, in line with CONSOB (Italy) and SEC (USA) guidance. Data is generated by AI from web sources and may contain errors or be out of date — always verify against the linked primary source. Do your own research and consult a licensed advisor. Full disclaimer: merlintrader.eu/disclaimer.

Avvertenza. Questo contenuto ha finalità esclusivamente didattiche e informative. Non costituisce consulenza finanziaria né una raccomandazione di acquisto o vendita di alcun titolo, in linea con le indicazioni CONSOB (Italia) e SEC (USA). I dati sono generati dall'AI a partire da fonti web e possono contenere errori o non essere aggiornati — verifica sempre rispetto alla fonte primaria collegata. Fai le tue ricerche e consulta un consulente autorizzato. Disclaimer completo: merlintrader.eu/disclaimer.